| Business: |
(Incorporated in the Cayman Islands)
We are a newly organized blank check company. We intend to focus our search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. We expect to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process.
Dr. Someit Sidhu serves as our chairman of the board and CEO. He is a strategy consultant and serial biotech entrepreneur in the industry. Dr. Sidhu is the founder of Khanda Therapeutics, and has served as its CEO and director since December 2025. Dr. Sidhu served as CEO and a director of JATT Acquisition Corp from its inception until JATT completed its business combination with Zura Bio in March 2023. From March 2023 to April 2024, Dr. Sidhu served as the CEO and director of Zura Bio, and has since continued to serve as director of Zura Bio. Dr. Sidhu was also a co-founder of Izana Bioscience and served as its CEO from November 2017 until its eventual sale to Roivant in June 2020. He is also co-founder of Pathios Therapeutics and Akaza Bioscience and has served as its CEO from 2019 to 2021. Prior to these companies, Dr. Sidhu advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on pharmaceutical R&D and portfolio strategy. Dr. Sidhu has also been serving as director of GSN Estate since September 2024 and as director of Invictus Bioscience since May 2016. Dr. Sidhu gained medical experience during his time in cardiology and general surgery after graduating from Oxford Medical School where he was a senior Mackinnon Scholar at Magdalen College..
Nicholas Fernandez serves as our CFO. He has over 20 years of experience across operations, accounting and finance. Mr. Fernandez was with Athanor Capital, a hedge fund, from December 2019 to December 2025, most recently serving as COO and CFO. From April 2024 to November 2024, Mr. Fernandez served as the COO, CFO and chief compliance officer of EcoBridge Capital Management. Previously, he was the CFO of the Asset Management and Alternative Investments Divisions of Jefferies LLC, a global bulge bracket investment bank, from February 2017 to April 2019. Prior to that, Mr. Fernandez worked at a variety of alternative investment managers in several capacities, progressing from a Fund Accountant to a Controller/Director of Operations. He started his career in public accounting with Ernst & Young in their Financial Services Office in New York, in their asset management practice with a concentration/serving Hedge, Private Equity and Venture Funds, as well as consulting. Mr. Fernandez has previously served as a director of Iris Acquisition Corp from May 2023 until its business combination with Liminatus Pharma, LLC in April 2025, and has been serving as a director of Liminatus Pharma, Inc., the post combination company since then. Mr. Fernandez has also been serving as the CFO of Amanat Acquisition Corp. since January 2026.
(Note: Jatt II Acquisition Corp. filed its S-1 on March 13, 2026, and disclosed the terms for its stock-only SPAC IPO: 6 million shares at $10.00 each to raise $60 million. Jatt II has not chosen a proposed symbol yet, according to the SEC filing.)
|
